US 11,717,515 B2
Treatment of migraine
Joel Trugman, Hoboken, NJ (US); Ramesh Boinpally, Princeton, NJ (US); Abhijeet Jakate, Edison, NJ (US); and Michelle Finnegan, Madison, NJ (US)
Assigned to Allergan Pharmaceuticals International Limited, Dublin (IE)
Filed by Allergan Pharmaceuticals International Limited, Dublin (IE)
Filed on Dec. 22, 2021, as Appl. No. 17/559,177.
Claims priority of provisional application 63/129,379, filed on Dec. 22, 2020.
Prior Publication US 2022/0193051 A1, Jun. 23, 2022
Int. Cl. A61K 31/4375 (2006.01); A61P 25/06 (2006.01); A61K 31/4545 (2006.01)
CPC A61K 31/4375 (2013.01) [A61K 31/4545 (2013.01); A61P 25/06 (2018.01)] 4 Claims
 
1. A method for the acute treatment of migraine with or without aura in a patient with severe hepatic impairment, the method comprising orally administering 50 mg of ubrogepant to the patient, wherein the patient has a Child-Pugh score of Child-Pugh Class C, and wherein the patient's migraine is safely and effectively treated.